Actavis

Last updated
Actavis Generics
Company type Subsidiary
NYSE: ACT
IndustryBranded and generic pharmaceuticals, and pharmaceutical research and development
FoundedMarch 1984;40 years ago (1984-03) in Libertyville, Illinois, United States
Founder Allen Chao, Ph.D. and David Hsia, Ph.D.
Defunct2015 (2015)
Fate2015 Irish tax inversion and merger with Allergan, Inc.
Successor Allergan, plc
Headquarters Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States
Number of locations
40 manufacturing facilities
27 global R&D centers
Area served
≈100 countries
Key people
Brenton L. Saunders (CEO and president)
Paul Bisaro (executive chairman)
ProductsBranded and generic pharmaceuticals
Revenue US$13.062 billion (2014)
Increase2.svg US$1.090 billion (2014)
Decrease2.svgUS$−1.63 billion (2014)
Total assets Increase2.svg US$6.881 billion (2014)
Total equity Increase2.svg US$28.335 billion (2014)
Number of employees
21,600 (2015)
Parent Teva Pharmaceuticals
Website www.actavis.com

Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc. ) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Contents

Actavis PLC markets brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women's Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. [2] The company's products include Botox, [3] Namenda, Restasis, [4] Linzess, Bystolic, [5] Juvederm, [6] Latisse, [7] Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex, [8] Optive, [9] Natrelle, [10] Viibryd, Liletta, Saphris, [11] Enablex, Actonel, Androderm, Gelnique and others.

Actavis PLC also operates the world's third-largest generics business. The company has been ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the US through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers more than 200 products. [12] Actavis PLC is also developing biosimilars products in oncology and other therapeutic categories, and currently has five biosimilar products in development. [13] Actavis PLC has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also included Anda Inc, the fourth-largest US generic pharmaceutical product distributor in the United States. [14]

On June 15, 2015, Actavis plc changed its name to Allergan plc, but the company's U.S. and Canadian generics business will continue to operate under the Actavis name. [15] In July 2015, Allergan PLC announced it would sell its Generics division of the company, including Anda Inc, [16] to Teva Pharmaceuticals for $40.5 billion, [17] [18] a transaction proposed for completion by the first quarter of 2016. [19]

History

The company was founded in the spring of 1983, [20] when, with funding from friends and family, colleagues Allen Chao, Ph.D. and David Hsia, Ph.D., began a small drug development enterprise. Just two months later, the founders established an initial product-development and analytical laboratory with six employees (including both founders) in a leased space in Libertyville, Illinois (U.S.).

By late fall of the same year, the company moved to Southern California into an initial 2,000-square-foot (190 m2) leased facility in Corona, and the development and manufacturing of generic pharmaceuticals began. [21] The Corona site became the corporate headquarters for the rapidly expanding US company.

Company evolution

1990s

Throughout its history, Actavis has expanded both organically and as the result of strategic acquisitions. In 1993, Actavis, then Watson, announced its initial public offering (IPO) of shares of common stock. The company was initially listed on the NASDAQ under the ticker symbol WATS. The company moved to the New York Stock Exchange (NYSE) in 1997, and began trading under the symbol WPI.

Actavis facility in Iceland Actavis.JPG
Actavis facility in Iceland

2000 to 2009

In 2000, the company acquired Schein Pharmaceutical Inc, an acquisition that more than doubled the company's size. [22] In that same year, the group reported revenues in excess of $1 billion. In the fall of 2006, it acquired Andrx Corporation, a Fort Lauderdale, FL–based pharmaceutical company founded by Alan Cohen, making it the third largest specialty pharmaceutical company based on total prescriptions dispensed. [23] In 2007, Dr. Allen Chao retired as President and Chief Executive Officer (CEO) and was succeeded by Paul M. Bisaro. [24] The company's international presence began with the acquisition of the Arrow Group in 2009, providing the company with commercial presence in more than 20 international markets. [25] As a result of the Arrow acquisition, the company also acquired the biopharmaceutical development organization Eden Biodesign in Liverpool, UK. [26]

2011 to 2014

In 2011, Watson moved its corporate headquarters from Corona, California to Parsippany, New Jersey. The new LEED-certified corporate headquarters at the Morris Corporate Center in Parsippany was formally dedicated on June 9, 2011. [27]

Actavis acquisition and Watson name change

In November 2012, Watson acquired the Switzerland-based, global generics company Actavis Group for €4.25 billion, creating the world's third largest generics company, with a leading position in key established commercial markets including the US, the UK, Nordics, Canada, Australia, and emerging markets in Central and Eastern Europe, and Russia. [28] Following the acquisition, Watson adopted Actavis' name for its global operations.

Warner Chilcott PLC acquisition

On October 1, 2013, Actavis acquired Irish pharmaceutical company Warner Chilcott PLC (previously known as Galen) in a stock-for-stock transaction valued at approximately $8.5 billion. [29] The combination created a company with approximately $10 billion in anticipated combined annual 2013 revenue, and the third-largest US specialty pharmaceutical company with approximately $3 billion in annual revenue focused on the core therapeutic categories of women's health, urology, gastroenterology and dermatology. In association with the merger the company relocated its corporate headquarters to Ireland while maintaining its operational headquarters in Parsippany, taking advantage of the lower (17% vs. 35% in the United States) Irish corporate tax rate. [30] This deal inspired a series of similar moves by other drug companies and led to new Treasury Department regulations limiting the ability of companies to perform such inversions, although Actavis was exempt from these regulations as its move abroad had already been completed. [31] CEO Paul Bisaro stated that in making the inversion, they were trying to "level the playing field" given the high corporate tax rate in the United States. [32]

Forest Laboratories acquisition

On July 1, 2014, Actavis announced that it had completed its acquisition of Forest Laboratories (who previously acquired, Furiex Pharmaceuticals Inc and Aptalis Pharma) in a cash and equity transaction valued at approximately $25 billion. [33] Following the acquisition, the company restructured its executive leadership, with Paul Bisaro being named Executive Chairman, and Brent Saunders being appointed CEO and President of the combined organization. [34]

Allergan Inc acquisition and Actavis PLC name change

In November 2014, Actavis PLC announced its intention to acquire Allergan Inc, the manufacturer of Botox. [35] Completion of the deal would increase its market capitalization to $147 billion. [36] [37] On March 17, 2015, Actavis PLC completed the acquisition of Allergan Inc in a cash and equity transaction valued at approximately $70.5 billion. The combination created a $23 billion diversified global pharmaceutical company with commercial reach across 100 countries. In June 2015, Actavis PLC officially changed its name to Allergan PLC. [38]

Teva Pharmaceuticals  
Actavis, PLC
 

Auden Mckenzie Holdings Limited
(Acq. 2015 by Actavis)

 

Durata Therapeutics
(Acq. 2014 by Actavis)

 

Forest Laboratories
(Acq. 2014 by Actavis)

Furiex Pharmaceuticals Inc
(Acq. 2014 by Forest)

Aptalis Pharma
(Eurand Pharmaceuticals & Axcan Pharma merged 2011,
Acq. 2014 by Forest)

 

Galen
(Acq. 2013 by Actavis)

Warner Chilcott PLC
(Acq. 2000 by Galen, adopted Warners name)

Procter & Gamble's prescription drug unit
(Acq. 2009 by Warner)

 

Watson Pharmaceuticals

Andrx Corporation
(Acq. 2006 by Watson)

 

Arrow Group
(Acq. 2009 by Watson)

 

Eden Biodesign
(Acq. by Watson)

 

Specifar Pharmaceuticals S.A.
(Acq. 2011 by Watson)

 

Ascent Pharmahealth Ltd
(Acq. 2012 by Watson)

 

Actavis Group
(Acq. 2012 by Watson, adopted Actavis' name)

Allergan Inc

Kythera Biopharmaceuticals
(Acq. 2015)

MAP Pharmaceuticals Inc
(Acq. 2013)

Inamed Corporation
(Acq. 2006)

Allergan
(Advanced Medical Optics spun off in 2006)

Locations and facilities

Global headquarters

The company's global headquarters are located in Dublin, Ireland and administrative headquarters are located in Parsippany, New Jersey, US. [39]

Manufacturing facilities

The company has 40 manufacturing facilities in five continents providing the company with a core leadership position in modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables. The company's manufacturing facilities are located in Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Iceland, India, Indonesia, Ireland, Northern-Ireland, Italy, Malta, Puerto Rico, Romania, Singapore, Serbia, Thailand, the UK and the US.[ citation needed ]

Research and development facilities

Actavis PLC has 27 global R&D facilities focusing on the development of modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables around the world. The company's R&D facilities are located in Belgium, Bulgaria, China, France, Iceland, Italy, India, Indonesia, Ireland, Japan, Romania, the UK and the US.[ citation needed ]

United Kingdom price fixing charges

In December 2016, the company was accused by the Competition and Markets Authority (CMA) of breaking competition law by "abuse of its dominant position" in the UK market and charging excessive and unfair prices". [40] It was alleged that the company had increased the price of hydrocortisone tablets by more than 12,000% over the course of eight years. It sold about 943,000 packets of the tablets to the National Health Service in 2015. 10 mg hydrocortisone tablets,, which were sold for 79p in April 2008, cost £88 per pack by March 2016; 20 mg hydrocortisone tablets in March 2008 were sold for £1.07, but £102.74 in 2016. From 2008 to 2015, NHS expenditure on the drug rose from £522,000 to £70 million. [41] The CMA reported its decision on 31 March 2022, confirming its findings of excessive and unfair prices being charged and anti-competitive agreements preventing the entry of potential competition into the market. [42]

Due to their production of "Promethazine With Codeine Cough Syrup", the main ingredient in recreational drug nicknamed 'lean', the brand has been name-dropped by multiple well known hip-hop artists. [43] [44] [45] Actavis discontinued production of the syrup in 2014. [46] However, Actavis have not ceased production of cough syrup containing hydrocodone and homatropine. Many rappers, such as Chief Keef and Future, mention Actavis cough syrup in their music.

Related Research Articles

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

<span class="mw-page-title-main">Warner Chilcott</span> American pharmaceutical company

Warner Chilcott was a company in the pharmaceutical industry based in Rockaway, New Jersey. It was primarily focused on women's healthcare and dermatology. On October 1, 2013, the company was acquired by Actavis.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

Sudocrem is an over-the-counter medicated cream aimed primarily at the treatment of nappy rash. It contains a water-repellent base ; protective and emollient agents; antibacterial and antifungal agents; and a weak anesthetic. As well as nappy rash, it can also be used to treat eczema, bedsores, minor burns, surface wounds, sunburn and chilblains. It was manufactured by pharmaceutical company Forest Laboratories Europe up until July 2014 when the company was acquired by, and combined with, Actavis plc. On March 17, 2015, Actavis completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. It's market presence is more than 100+ countries.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.

David Edmund Ian Pyott CBE was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. In 2014 he was one of the 25 highest-paid CEOs in the United States.

<span class="mw-page-title-main">Greenhill & Co.</span> American investment bank

Greenhill & Co., Inc. is an American investment banking advisory firm founded in 1996 by Robert F. Greenhill. The firm provides advice on significant mergers, acquisitions, restructurings, financings, and capital raisings to leading corporations, partnerships, institutions and governments across a number of industries. Since its inception, Greenhill has advised on transactions valued at close to $3 trillion.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

References

  1. ↑ "Analyst cuts Allergan generics sales estimates as Teva deal close nears". FiercePharma. 16 June 2016.
  2. ↑ "Form 10K". Actavis plc.
  3. ↑ "Botox cosmetics". Allergan.
  4. ↑ "Restasis" (PDF). Allergan.
  5. ↑ Barr, Diana (18 February 2014). "Forest Labs to be sold for $25 billion". St. Louis Business Journal.
  6. ↑ "Juvederm". Allergan.
  7. ↑ "Latisse" (PDF). Allergan.
  8. ↑ "Ozurdex". Allergan.
  9. ↑ "Optive". Allergan.
  10. ↑ "Natrelle". Allergan.
  11. ↑ "Form 10K". Actavis plc.
  12. ↑ "Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES Patent Suit". First Word Pharma.
  13. ↑ John Carroll (18 February 2015). "Can Actavis deliver a promised $6B boost from this pipeline". Fierce Biotech.
  14. ↑ "Actavis Confirms Favorable Ruling In Generic Pulmicort Respules Patent Suit". First Word Pharma.
  15. ↑ Haggerty, Neil (2015-06-15). "Actavis Changes Name to Allergan After Deal for Botox Maker". WSJ. Retrieved 2015-08-07.
  16. ↑ "Teva Completes Acquisition of Actavis Generics". www.businesswire.com. 2016-08-02. Retrieved 2019-03-06.
  17. ↑ "Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion" (Press release). Allergan. 27 July 2015. Retrieved 4 December 2015.
  18. ↑ Yoel, Minkoff (27 July 2015). "Teva to buy Allergan Generics for $40.5B". Seeking Alpha. Retrieved 4 December 2015.
  19. ↑ O'Donnell, Carl (3 December 2015). "Teva divesting $1 billion in assets to clear Allergan deal". Reuters. Retrieved 4 December 2015– via Yahoo! Finance.
  20. ↑ "ACT Profile | Actavis plc Ordinary Shares Stock - Yahoo! Finance". yahoo.com. Archived from the original on 2015-04-13.
  21. ↑ "Watson Pharmaceuticals acquired Arrow Group for 1.75B". TBI. Archived from the original on 2015-04-02.
  22. ↑ "Watson Pharmaceuticals agrees to buy a rival". NY Times. 2000-05-26.
  23. ↑ "Watson Pharmaceuticals to buy Andrx Corp". PharmacyTimes.com. April 2006.
  24. ↑ "Watson Pharmaceuticals, Inc. Says CEO to Retire, Names Replacement". Fierce Biotech. 2 August 2007.
  25. ↑ "Watson to acquire Arrow Group for $1.75 billion". Marketwatch. 2009-06-17.
  26. ↑ Gareth Macdonald (February 2010). "Watson buys Eden Biodesign". Biopharma-Reporter.com.
  27. ↑ "Generic drug maker Watson opening research operations in North Brunswick". NJ.com. 30 January 2012.
  28. ↑ Eyk Henning (2012-04-25). "Watson, Actavis to Merge in €4.5 Billion Deal". Wall Street Journal.
  29. ↑ "News - Actavis". Actavis. Archived from the original on 2016-01-16.
  30. ↑ Loftus, Peter (2013-05-20). "Actavis to Buy Warner Chilcott in $5 Billion Deal". The Wall Street Journal.
  31. ↑ Gelles, David (2014-11-17). "Allergan Escapes Valeant's Pursuit, Agreeing to Be Bought by Actavis". The New York Times.
  32. ↑ Drew Armstrong (2013-05-21). "Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal". Bloomberg.com.
  33. ↑ Wainer, David (2014-02-18). "Actavis to buy Forest Laboratories for 25 billion". Bloomberg.
  34. ↑ "GEN - News Highlights:Actavis Deal's a Dandy for Activist Icahn". GEN.
  35. ↑ "BBC News - Actavis to buy Botox-maker Allergan $66bn". BBC News. 17 November 2014.
  36. ↑ Caroline Chen (2014-11-17). "Actavis Surges to Top Drugmaker Ranks With Acquisitions". Bloomberg.com.
  37. ↑ Willhite, James (2014-11-17). "The Morning Ledger: Actavis Could Again Evade Treasury's Grasp for Post-Inversion Tax Break". WSJ.
  38. ↑ "Actavis plc is now Allergan plc". Archived from the original on 5 May 2016. Retrieved 16 June 2015.
  39. ↑ "Actavis plc". MarketWatch. 22 May 2023.
  40. ↑ Competition and Markets Authority, Hydrocortisone tablets: alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct (50277), last updated 31 March 2022, accessed 1 June 2023
  41. ↑ "NHS overcharged by 12,000% for hydrocortisone tablets by drug company Actavis, CMA claims" . Independent. 16 December 2016. Archived from the original on 2016-12-17. Retrieved 16 December 2016.
  42. ↑ UKOpenGovernmentLicence.svg  This article incorporates text published under the British Open Government Licence : Competition and Markets Authority, Decision: Hydrocortisone tablets. Excessive and unfair pricing and Anti-competitive agreements , published 31 March 2022, accessed 1 June 2023
  43. ↑ "Future – Thought It Was a Drought". Genius Lyrics.
  44. ↑ "Frank Ocean – Chanel". Genius Lyrics.
  45. ↑ Lil Pump (Ft. Lil Uzi Vert) – Multi Millionaire , retrieved 2018-10-08
  46. ↑ "Sizzurp Cough Syrup Off the Market". TMZ. April 23, 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.